Lymphoma, T-Cell, Peripheral - 15 Studies Found
| Completed |
: Treatment of Peripheral T-cell Lymphoma : Peripheral T-cell Lymphoma : 2012-08-10 :
|
| Completed |
: CHO(E)P-14 Followed by Alemtuzumab Consolidation in Peripheral T Cell Lymphoma : Peripheral T-Cell Lymphoma : 2013-02-25 : Drug: Alemtuzumab Consolidation after CHOP induction |
| Completed |
: Study of Bortezomib Combined With ACVBP in Peripheral T-Cell Lymphoma : Peripheral T-Cell Lymphoma : 2005-08-26 : Drug: Velcade + ACVBP regimen |
| Active, not recruiting |
: A Trial of Romidepsin for Progressive or Relapsed Peripheral T-cell Lymphoma : Peripheral T-cell Lymphoma : 2007-01-23 : Drug: Romidepsin Romidepsin intravenously (through a vein) over 4 hours on Days 1, 8 and 15 of each 28-d |
| Completed |
: Study of KW-0761 (Mogamulizumab) in Subjects With Previously Treated Peripheral T-cell Lymphoma (PTCL) : Peripheral T-Cell Lymphoma : 2012-05-30 : Biological: KW-0761 (mogamulizumab) 1 mg/kg administered intravenously weekly x 4 then every other week |
| Not yet recruiting |
: Clinical Trial of Chidamide Combined With CHOP in Peripheral T-cell Lymphoma Patients : Peripheral T-cell Lymphoma : 2016-06-17 :
|
| Terminated |
: Pilot Study of Brentuximab Vedotin in Relapsed/Refractory Peripheral T-Cell Lymphoma Expressing CD30 : Peripheral T-Cell Lymphoma : 2013-04-24 : Drug: Brentuximab vedotin Brentuximab vedotin will be given by intravenous infusion (into a vein) on Day |
| Completed |
: Belinostat in Relapsed or Refractory Peripheral T-Cell Lymphoma : Peripheral T-cell Lymphoma : 2009-03-19 : Drug: PXD101 Belinostat (PXD101) 1000 mg/m²administered as a 30 minute IV infusion on days 1-5 of e |
| Recruiting |
: GDP in Frontline Chemotherapy for Patients With PTCL-NOS : Lymphoma, T-Cell, Peripheral : 2015-03-26 : Drug: GDP chemotherapy gemcitabine (1000mg/m2 intravenously over 30 minutes on days 1 and 8), cisplatin |
| Completed |
: Study of Pralatrexate With Vitamin B12 and Folic Acid in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma : Peripheral T-cell Lymphoma : 2006-08-14 : Drug: Pralatrexate Injection Pralatrexate 30 mg/m2 via IV push over 3-5 minutes for 6 weeks in a 7 week |